@inproceedings{oai:repo.qst.go.jp:00054306,
 author = {Koto, Masashi and Hasegawa, Azusa and Takagi, Ryo and Fujikawa, Akira and Morikawa, Takamichi and Tsujii, Hirohiko and Kamada, Tadashi and 小藤 昌志 and 長谷川 安都佐 and 高木 亮 and 藤川 陽 and 森川 貴迪 and 辻井 博彦 and 鎌田 正},
 book = {NIRS-ETOILE Joint Symposium on Carbon Ion Radiotherapy},
 issue = {NIRS-M-243},
 month = {Nov},
 note = {Purpose: To estimate the toxicity and efficacy of carbon ion radiotherapy for skull base and paracervical tumors in clinical trials.
Patients and Methods: A phase I/II dose escalation study for skull base and paracervical tumors was initiated in April 1997. The patients were treated with 16 fractions for 4 weeks with a total dose of 48.0, 52.8, 57.6, or 60.8Gy equivalents (GyE). In April of 2004, a phase II study was initiated with an irradiation schedule of 60.8GyE in 16 fractions over four weeks. There were 76 patients included in the analysis. Histologically, 44 patients had chordoma, 12 chondrosarcoma, 9 olfactory neuroblastoma, 7 malignant meningioma, 1 giant cell
tumor, and 1 had a neuroendocrine carcinoma. The patients were treated with a dose of 48.0 GyE (4 patients), 52.8 GyE (6 patients), 57.6 GyE (9 patients) or 60.8 GyE (57 patients).
 Results: The follow-up periods ranged from 3 to 158 months, with a median period of 46 months. At the time of the analysis, there was no evidence of any serious acute (Grade ≥4 ) or late (Grade ≥3) reactions. The 5-year local control and overall survival rates for all patients were 88% and 82%, respectively. The 5-year local control and overall survival rates for chordoma patients were 88% and 87%, respectively.
 Conclusion: A carbon ion dose of 60.8GyE in 16 fractions was effective and safe for the treatment of skull base and paracervical tumors.},
 pages = {12--17},
 publisher = {National Institute of Radiological Sciences},
 title = {Carbon Ion Radiotherapy for Skull Base and Paracervical Tumors},
 volume = {2nd},
 year = {2011}
}